Skip to main content
MOLN
NASDAQ Life Sciences

Molecular Partners Doses First Patients in Phase 1/2a Trial for Lead Radio-DARPin MP0712

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.93
Mkt Cap
$156.336M
52W Low
$3.41
52W High
$5.36
52W Position info
15% above low
Off High info
27% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

MOLN sits 15% above its 52-week low of $3.41.

Summary

Molecular Partners and Orano Med announced the dosing of the first patients in a Phase 1/2a clinical trial for MP0712, their lead DLL3-targeting Radio-DARPin candidate for small cell lung cancer.


Key Events · Product Development and Regulatory · MOLN

  • First Patients Dosed in Phase 1/2a Trial

    The lead Radio-DARPin candidate, MP0712, targeting DLL3 for small cell lung cancer, has begun dosing patients in a US multicenter Phase 1/2a study.

  • Strategic Partnership with Orano Med

    MP0712 is being developed under a strategic partnership with Orano Med, a radiopharmaceutical company specializing in lead-212 (212Pb) based therapies.

  • Upcoming Data Milestones

    Initial study data is expected in the coming months (2026), with comprehensive efficacy data anticipated in 2027.

  • DLL3 Target for SCLC

    MP0712 targets DLL3, a protein highly expressed in over 85% of small cell lung cancer tumors and other aggressive neuroendocrine tumors.


Analysis · MOLN · Life Sciences

This filing announces a significant clinical milestone for Molecular Partners, as its lead Radio-DARPin candidate, MP0712, has begun dosing patients in a Phase 1/2a trial. This advancement validates the company's platform and moves a key asset closer to potential commercialization, providing a clear timeline for initial data in 2026 and comprehensive efficacy data in 2027.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MOLN was trading at $3.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $156.3M. The 52-week trading range was $3.41 to $5.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MOLN - Latest Insights

MOLN
Oct 29, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.71
Real-time Price: $2.70 info
Change: -$1.01 (-27%) info
Market Cap: $115.475M info
MOLN
Aug 25, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.40
Real-time Price: $2.70 info
Change: -$1.70 (-39%) info
Market Cap: $115.475M info
MOLN
Jul 16, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.91
Real-time Price: $2.70 info
Change: -$1.21 (-31%) info
Market Cap: $115.475M info
MOLN
Jul 06, 2026, 6:00 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.99
Real-time Price: $2.70 info
Change: -$1.29 (-32%) info
Market Cap: $115.475M info
MOLN
May 12, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $2.70 info
Change: -$1.34 (-33%) info
Market Cap: $115.475M info